Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
InterDigital
IDCC
$8.88B
| $44.4M | 0.06% |
574,574
+98,874
| +21% | +$8.29M |
|
427
Coeur Mining
CDE
$19B
| $44.3M | 0.06% |
5,164,228
-751,500
| -13% | -$6.83M |
|
|
CATM
428
DELISTED
Cardtronics plc Class A Ordinary Shares (UK)
CATM
| $44.2M | 0.06% |
1,346,200
+593,200
| +79% | +$22.2M |
|
|
DF
429
DELISTED
Dean Foods Company
DF
| $44.2M | 0.06% |
2,599,750
+879,800
| +51% | +$16.5M |
|
430
Choice Hotels
CHH
$4.71B
| $44.1M | 0.06% |
686,800
+165,000
| +32% | +$10.6M |
|
|
PX
431
DELISTED
Praxair Inc
PX
| $44.1M | 0.06% |
332,700
-1,228,000
| -79% | -$157M |
|
|
PDM
432
Piedmont Realty Trust
PDM
$1.2B
| $44M | 0.06% |
2,087,500
+184,176
| +10% | +$3.98M |
|
|
SODA
433
DELISTED
SodaStream International Ltd
SODA
| $43.8M | 0.06% |
818,500
+113,500
| +16% | +$6.03M |
|
434
Albany International
AIN
$1.82B
| $43.8M | 0.06% |
820,000
-34,500
| -4% | -$1.67M |
|
|
TWTR
435
DELISTED
Twitter, Inc.
TWTR
| $43.7M | 0.06% |
+2,445,100
| New | +$41.7M |
|
436
Cinemark Holdings
CNK
$4.37B
| $43.5M | 0.06% |
1,118,700
-64,100
| -5% | -$2.66M |
|
437
Casella Waste Systems
CWST
$5.79B
| $43.4M | 0.06% |
2,644,942
+322,600
| +14% | +$4.77M |
|
438
Cavco Industries
CVCO
$4.67B
| $43.3M | 0.06% |
334,200
+10,700
| +3% | +$1.28M |
|
439
Textron
TXT
$15.1B
| $43.3M | 0.06% |
919,900
+212,700
| +30% | +$10M |
|
440
Methode Electronics
MEI
$593M
| $43.2M | 0.06% |
1,047,880
+41,580
| +4% | +$1.74M |
|
441
Corpay
CPAY
$27.9B
| $43.1M | 0.06% |
298,900
-231,900
| -44% | -$33.1M |
|
|
AF
442
DELISTED
Astoria Financial Corporation
AF
| $43.1M | 0.06% |
2,137,250
-229,100
| -10% | -$4.54M |
|
443
Cintas
CTAS
$80.3B
| $43M | 0.05% |
1,364,272
+1,098,000
| +412% | +$34.2M |
|
444
Eagle Materials
EXP
$6.41B
| $42.9M | 0.05% |
464,700
+419,500
| +928% | +$40.3M |
|
445
Extreme Networks
EXTR
$3.16B
| $42.9M | 0.05% |
4,649,961
| – | – |
|
446
Fortive
FTV
$18.7B
| $42.8M | 0.05% |
1,072,453
+555,811
| +108% | +$21.9M |
|
447
Flex
FLEX
$45.9B
| $42.7M | 0.05% |
3,473,760
+3,359,240
| +2,933% | +$41.6M |
|
448
Vulcan Materials
VMC
$36B
| $42.7M | 0.05% |
336,965
+99,000
| +42% | +$12.4M |
|
|
NFX
449
DELISTED
Newfield Exploration
NFX
| $42.5M | 0.05% |
+1,494,800
| New | +$49.2M |
|
|
CCMP
450
DELISTED
CMC Materials, Inc. Common Stock
CCMP
| $42.3M | 0.05% |
573,109
+145,109
| +34% | +$11M |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.